Daliresp

Generic name

Roflumilast

Covered by Medicare

Yes

Get a Medicare Quote

Average Annual Cost per Beneficiary

$3,193.71

Average cost per year*

Average Annual Cost per Dose

$13.83

9.27%

Average cost per beneficiary*

Manufacturer(s)

  • Astrazeneca

What is Daliresp

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. NOTE: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

Drug Trends

*Origin of the terms and chart data used within this page: https://data.cms.gov/

Common Questions About Daliresp

Yes, Daliresp is covered by Medicare.

In 2021, the average cost per dose of Daliresp was $13.83.

The average dose of Daliresp received per year is 14,007,918 units

62,354 Medicare beneficiaries received Daliresp in 2021, which was a -0.03% from 2020

There were 347,524 claims made by Medicare beneficiaries, which is a -0.06% from 2020

The average spending amount per claim in 2021 was $573.03

The average Medicare spending per beneficiary amount for Daliresp was $3,193.71

Astrazeneca received $199,140,335.32

The total amount spent on Daliresp by Medicare is $199,140,335.32

© 2021-2024 HealthInsurance.com, LLC

Privacy Policy  |  Terms and Conditions

GENERAL DISCLAIMERS

Healthinsurance.com is a commercial site designed for the solicitation of insurance from selected health insurance carriers and HealthInsurance.com, LLC is a licensed insurance agency. It is not a government agency. It is also not an insurer, or a medical provider. HealthInsurance.com, LLC is a licensed representative of Medicare Advantage (HMO, PPO, PFFS, and PDP) organizations that have a Medicare contract. Enrollment depends on the plan’s contract renewal.
We do not offer every plan available in your area. Currently we represent nine carrier plan organizations nationally. Please contact Medicare.gov, 1-800-MEDICARE, or your local State Health Insurance Program (SHIP) to get information on all of your options.
Alternatively, you may be referred, via a link, to a selected partner website, which is independently owned and operated and may have different privacy and terms of use policies from us.
If you provide your contact information to us, an insurance agent/producer or insurance company may contact you. If you do not speak English, language assistance service, free of charge, is available to you; contact the toll-free number listed above. This site is not maintained by or affiliated with the federal government's Health Insurance Marketplace website or any state government health insurance marketplace.
The plans we represent do not discriminate on the basis of race, color, national origin, age, disability, or sex. To learn more about a plan's nondiscrimination policy, please click here.
Not all plans offer all of these benefits. Benefits may vary by carrier and location. Limitations and exclusions may apply.
Multi-Plan_HIC_Web_M